S&P 500   3,296.57 (-0.41%)
DOW   26,561.92 (-0.36%)
QQQ   273.84 (-0.92%)
AAPL   110.56 (-4.13%)
MSFT   202.78 (-0.95%)
FB   277.50 (-1.19%)
GOOGL   1,665.32 (+6.97%)
AMZN   3,156.00 (-1.71%)
TSLA   406.80 (-0.98%)
NVDA   513.50 (-1.43%)
BABA   308.53 (-1.29%)
GE   7.32 (-0.68%)
MU   49.86 (-1.23%)
AMD   77.20 (-1.05%)
T   26.65 (-0.41%)
F   7.87 (-0.38%)
GILD   57.65 (-1.50%)
NIO   31.45 (-1.69%)
NFLX   500.91 (-0.65%)
BA   147.19 (-0.74%)
DIS   120.59 (-0.78%)
S&P 500   3,296.57 (-0.41%)
DOW   26,561.92 (-0.36%)
QQQ   273.84 (-0.92%)
AAPL   110.56 (-4.13%)
MSFT   202.78 (-0.95%)
FB   277.50 (-1.19%)
GOOGL   1,665.32 (+6.97%)
AMZN   3,156.00 (-1.71%)
TSLA   406.80 (-0.98%)
NVDA   513.50 (-1.43%)
BABA   308.53 (-1.29%)
GE   7.32 (-0.68%)
MU   49.86 (-1.23%)
AMD   77.20 (-1.05%)
T   26.65 (-0.41%)
F   7.87 (-0.38%)
GILD   57.65 (-1.50%)
NIO   31.45 (-1.69%)
NFLX   500.91 (-0.65%)
BA   147.19 (-0.74%)
DIS   120.59 (-0.78%)
S&P 500   3,296.57 (-0.41%)
DOW   26,561.92 (-0.36%)
QQQ   273.84 (-0.92%)
AAPL   110.56 (-4.13%)
MSFT   202.78 (-0.95%)
FB   277.50 (-1.19%)
GOOGL   1,665.32 (+6.97%)
AMZN   3,156.00 (-1.71%)
TSLA   406.80 (-0.98%)
NVDA   513.50 (-1.43%)
BABA   308.53 (-1.29%)
GE   7.32 (-0.68%)
MU   49.86 (-1.23%)
AMD   77.20 (-1.05%)
T   26.65 (-0.41%)
F   7.87 (-0.38%)
GILD   57.65 (-1.50%)
NIO   31.45 (-1.69%)
NFLX   500.91 (-0.65%)
BA   147.19 (-0.74%)
DIS   120.59 (-0.78%)
S&P 500   3,296.57 (-0.41%)
DOW   26,561.92 (-0.36%)
QQQ   273.84 (-0.92%)
AAPL   110.56 (-4.13%)
MSFT   202.78 (-0.95%)
FB   277.50 (-1.19%)
GOOGL   1,665.32 (+6.97%)
AMZN   3,156.00 (-1.71%)
TSLA   406.80 (-0.98%)
NVDA   513.50 (-1.43%)
BABA   308.53 (-1.29%)
GE   7.32 (-0.68%)
MU   49.86 (-1.23%)
AMD   77.20 (-1.05%)
T   26.65 (-0.41%)
F   7.87 (-0.38%)
GILD   57.65 (-1.50%)
NIO   31.45 (-1.69%)
NFLX   500.91 (-0.65%)
BA   147.19 (-0.74%)
DIS   120.59 (-0.78%)
Log in
NASDAQ:NVCR

Novocure Stock Forecast, Price & News

$123.27
+7.88 (+6.83 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$116.50
Now: $123.27
$125.79
50-Day Range
$85.45
MA: $116.31
$138.72
52-Week Range
$53.40
Now: $123.27
$140.89
Volume1.29 million shs
Average Volume1.00 million shs
Market Capitalization$12.46 billion
P/E Ratio1,027.34
Dividend YieldN/A
Beta1.41
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

Market Cap$12.46 billion
Next Earnings DateN/A
OptionableOptionable
$123.27
+7.88 (+6.83 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock price been impacted by Coronavirus (COVID-19)?

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 82.9% and is now trading at $123.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novocure?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure
.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its earnings results on Thursday, October, 29th. The medical equipment provider reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The medical equipment provider had revenue of $132.70 million for the quarter, compared to the consensus estimate of $120.02 million. Novocure had a net margin of 2.88% and a return on equity of 5.14%. The firm's quarterly revenue was up 44.1% on a year-over-year basis. During the same period last year, the company posted $0.02 earnings per share.
View Novocure's earnings history
.

What price target have analysts set for NVCR?

10 Wall Street analysts have issued 12-month price objectives for Novocure's stock. Their forecasts range from $58.00 to $140.00. On average, they expect Novocure's stock price to reach $92.33 in the next twelve months. This suggests that the stock has a possible downside of 25.1%.
View analysts' price targets for Novocure
.

Are investors shorting Novocure?

Novocure saw a increase in short interest in September. As of September 30th, there was short interest totaling 5,330,000 shares, an increase of 41.4% from the September 15th total of 3,770,000 shares. Based on an average trading volume of 961,000 shares, the short-interest ratio is currently 5.5 days. Currently, 6.4% of the shares of the company are sold short.
View Novocure's Short Interest
.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Who are Novocure's major shareholders?

Novocure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.41%), Peregrine Capital Management LLC (0.13%), Scout Investments Inc. (0.10%), State of New Jersey Common Pension Fund D (0.06%), Taylor Frigon Capital Management LLC (0.05%) and Hodges Capital Management Inc. (0.04%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for Novocure
.

Which institutional investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, CWM LLC, Envestnet Asset Management Inc., and IFP Advisors Inc. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure
.

Which institutional investors are buying Novocure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Hodges Capital Management Inc., Rhenman & Partners Asset Management AB, Eagle Global Advisors LLC, Standard Life Aberdeen plc, IBM Retirement Fund, NewFocus Financial Group LLC, and Avantax Advisory Services Inc..
View insider buying and selling activity for Novocure
.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $123.27.

How big of a company is Novocure?

Novocure has a market capitalization of $12.46 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Novocure's official website?

The official website for Novocure is www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.